shlokn/autogkb huggingface dataset:
Article: Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients
Gene: EPHX1
Variant/haplotype: rs1051740
Drug(s): carbamazepine
Phenotype category: Metabolism/PK
Significant: no
Association: Genotype CC is not associated with dose of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.
Notes: There was no association between dose (mean daily, or mean maintenance) with the genotype.
Article: Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial
Gene: OPRM1
Variant/haplotype: rs548646
Drug(s): naltrexone
Phenotype category: Efficacy
Significant: no
Association: Allele T is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele C.
Notes: No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. Please note that alleles have been complemented to the positive strand.
Article: Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients
Gene: ATM
Variant/haplotype: rs11212617
Drug(s): metformin
Phenotype category: Efficacy
Significant: no
Association: Allele C is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.
Notes: in Iranian patients. Response to metformin was defined by HbA1c and fasting blood sugar (FBS) values.
Article: Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia
Gene: SLCO1B1
Variant/haplotype: rs10841753
Drug(s): methotrexate
Phenotype category: Efficacy
Significant: no
Association: Allele C is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.
Article: Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients
Gene: HTR6
Variant/haplotype: rs1805054
Drug(s): risperidone
Phenotype category: Efficacy
Significant: no
Association: Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.
Article: Genetic Variation in CYP3A43 Explains Racial Difference in Olanzapine Clearance
Gene: CYP3A43
Variant/haplotype: rs17161983
Drug(s): olanzapine
Phenotype category: Metabolism/PK
Significant: no
Association: Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.
Article: Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities
Gene: CYP2B6
Variant/haplotype: rs4803419
Drug(s): S-EDDP
Phenotype category: Metabolism/PK
Significant: no
Association: Allele T is not associated with concentrations of (S)-EDDP as compared to allele C.
Article: Genome-wide Association Identifies the T Gene as a Novel Asthma Pharmacogenetic Locus
Gene: TBXT
Variant/haplotype: rs2305089
Drug(s): flunisolide
Phenotype category: Efficacy
Significant: yes
Association: Genotype TT is associated with increased response to flunisolide in people with Asthma as compared to genotypes CC + CT.
Notes: Response to flunisolide was measured by the difference between prebronchodilator FEV1 off the drug and prebronchodilator FEV1 on the drug. FEV1 off flunisolide was measured during a placebo run-in period, and FEV1 on flunisolide was measured after 8 weeks (for the CAMP population) or 6 weeks (for the ACRN population) of therapy with the drug. Please note that the associated alleles were not specified by letter in the paper, but rather identified as mutant or wild-type. dbSNP was used to assess which alleles were mutant and which were wild-type.
Article: Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis
Gene: DRD2
Variant/haplotype: rs2514218
Drug(s): aripiprazole, risperidone
Phenotype category: Efficacy
Significant: yes
Association: Genotype CC is associated with increased response to aripiprazole or risperidone in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT.
Notes: Patients with the CC genotype had a greater reduction in symptoms over 12 weeks of treatment with either aripiprazole or risperidone.
Article: Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients
Gene: SLCO1B3
Variant/haplotype: rs11045585
Drug(s): docetaxel
Phenotype category: Other, Metabolism/PK
Significant: yes
Association: Allele G is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms.
Notes: Significance as part of a haplotype with rs4149118, rs7311358 and rs3834935.
Article: Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers
Gene: CYP2C19
Variant/haplotype: rs12769205
Drug(s): AR-C124910XX, ticagrelor
Phenotype category: Metabolism/PK
Significant: no
Association: Genotypes AG + GG is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype AA.
Notes: from TABLE 4 Ticagrelor pharmacokinetic parameters based on genotypes without statistical significance and TABLE 5; AR-C124910XX pharmacokinetic parameters based on genotypes without statistical significance
Article: Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer
Gene: CYP1B1
Variant/haplotype: rs1056827
Drug(s): exemestane
Phenotype category: Metabolism/PK
Significant: no
Association: Genotypes AA + AC are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to genotype CC.
Notes: No significant difference in exemestane concentrations were seen between the three genotypes. Please note that alleles have been complemented to the plus chromosomal strand.
Article: Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
Gene: CYP2D6
Variant/haplotype: CYP2D6*1, CYP2D6*41
Drug(s): 4-hydroxytamoxifen, endoxifen, N-desmethyltamoxifen, tamoxifen
Phenotype category: Metabolism/PK
Significant: no
Association: CYP2D6 *41 is not associated with concentrations of 4-hydroxytamoxifen, endoxifen, N-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.
Notes: Patients (pre- (83%) and postmenopausal (17%)) with ER and/or PR positive breast tumors, which received 20 mg tamoxifen daily. Patients taking CYP2D6 inhibitors were excluded. DNA extracted from blood and screened for the following: *2 (2850C>T; rs16947), *2A (–1584C>G), *3 (2549delA; rs35742686), *4 (1846G>A; rs3892097), *5 (CYP2D6del), *6 (1707delT; rs5030655), *7 (2935A>C; rs5030867), *8 (1758G>T), *9 (2615-2617delAAG; rs5030656), *10 (100C>T; rs1065852), *12 (124G>A; rs5030862), *14 (1758G>A), *17 (1023C>T; rs28371706), *29 (1659G>A; rs61736512), *41 (2988G>A; rs28371725) and *xN (dup). [pre-menopausal][post-menopausal] [adjuvant] [DNA source: blood]
Article: The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients
Gene: TYMS
Variant/haplotype: rs45445694
Drug(s): methotrexate
Phenotype category: Efficacy
Significant: yes
Association: Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased clinical benefit to methotrexate in people with Arthritis, Rheumatoid as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2.
Notes: "Also, a significant difference was found in TYMS 2R/3R (rs34743033) among the dominant model, p = 0.022, OR = 0.165 (0.035–0.771), and the heterozygous genetic model, p = 0.013, OR = 0.129 (0.026–0.644)." rs34743033 is equivalent to rs45445694. Authors label 2R as reference.
Article: New genetic variant that might improve warfarin dose prediction in African Americans
Gene: EPHX1
Variant/haplotype: rs1051741
Drug(s): warfarin
Phenotype category: Dosage
Significant: yes
Association: Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.
Notes: in Caucasians. However,this SNP was no longer statistically significantly associated with warfarin dosing after accounting for the number of tag SNPS the authors; evaluated within the EPHX1 gene.
Article: The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)‐Warfarin
Gene: CYP2C9
Variant/haplotype: CYP2C9*1, CYP2C9*2, CYP2C9*11
Drug(s): warfarin
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP2C9 *1/*11 + *2/*11 is associated with decreased clearance of warfarin in healthy individuals as compared to CYP2C9 *1/*1.
Notes: Effect was for S-warfarin but not R-warfarin. It was also significant for increased halflife of S-warfarin but not R-warfarin.
Article: Effect of UGT2B10, UGT2B17, FMO3, and OCT2 Genetic Variation on Nicotine and Cotinine Pharmacokinetics and Smoking in African Americans
Gene: UGT2B10
Variant/haplotype: rs61750900
Drug(s): nicotine
Phenotype category: Metabolism/PK
Significant: no
Association: Genotype GG is not associated with metabolism of nicotine in people with Tobacco Use Disorder as compared to genotype GT.
Notes: This SNP is not associated with the pharmacokinetic measures of nicotine.
Article: Genetic Polymorphisms of Cytokines Might Affect Postoperative Sufentanil Dosage for Analgesia in Patients
Gene: IL1B
Variant/haplotype: rs16944
Drug(s): sufentanil
Phenotype category: Dosage
Significant: no
Association: Allele G is not associated with dose of sufentanil in people with Pain, Postoperative as compared to allele A.
Article: Influence of Methylenetetrahydrofolate Reductase C677T, A1298C, and G80A Polymorphisms on the Survival of Pediatric Patients with Acute Lymphoblastic Leukemia
Gene: SLC19A1
Variant/haplotype: rs1051266
Drug(s): methotrexate
Phenotype category: Efficacy
Significant: yes
Association: Genotypes CC + TT are associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT.
Notes: Patients with the CT genotype had better overall survival than patients with the CC or TT genotypes. Variant referred to in the paper as G80A. Please note that alleles have been complemented to the positive strand.
Article: CYP2C9*8 is prevalent among African–Americans: implications for pharmacogenetic dosing
Gene: VKORC1
Variant/haplotype: rs72547529
Drug(s): warfarin
Phenotype category: Dosage
Significant: not stated
Association: Allele T is associated with increased dose of warfarin as compared to allele C.
Notes: 3 warfarin resistant g.1331G>A (p.V66M) carriers were identified (1 in ~100 individuals) suggesting this variant is associated with warfarin resistance.
Article: Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population
Gene: SLCO1B3
Variant/haplotype: rs7311358
Drug(s): warfarin
Phenotype category: Dosage
Significant: yes
Association: Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.
Article: The Distribution of the Genotypes of ABCB1 and CES1 Polymorphisms in Kazakhstani Patients with Atrial Fibrillation Treated with DOAC
Gene: CES1
Variant/haplotype: rs8192935
Drug(s): dabigatran
Phenotype category: Metabolism/PK
Significant: yes
Association: Genotypes AA + AG is associated with decreased dose-adjusted trough concentrations of dabigatran in people with Atrial Fibrillation as compared to genotype GG.
Notes: "Our study showed that patients with GG genotype (138.8 ± 100.1 ng/mL) had higher peak plasma concentration of dabigatran than with AA genotype (100.9 ± 59.6 ng/mL), and AG genotype (98.7 ± 72.3 ng/mL) (Kruskal–Wallis test, p = 0.25)." "Our study showed that polymorphism rs8192935 in the CES1 gene was significantly associated with plasma concentrations of dabigatran in Kazakhstani NVAF patients." In supplementary table S5 significant p values are given for Multinomial Logistic Regression analysis.
Article: PHARMACOGENOMIC GENOME-WIDE META-ANALYSIS OF BLOOD PRESSURE RESPONSE TO BETA-BLOCKERS IN HYPERTENSIVE AFRICAN AMERICANS
Gene: SLC25A31
Variant/haplotype: rs201279313
Drug(s): atenolol, hydrochlorothiazide, metoprolol
Phenotype category: Efficacy
Significant: yes
Association: Genotype TTA/del is associated with increased response to atenolol, hydrochlorothiazide or metoprolol in people with Hypertension as compared to genotype TTA/TTA.
Notes: Study in African Americans
Article: PDE4 Gene Family Variants Are Associated with Response to Apremilast Treatment in Psoriasis
Gene: CYP3A4, TMEM130
Variant/haplotype: rs1203844
Drug(s): apremilast
Phenotype category: Efficacy
Significant: yes
Association: Allele C is associated with increased clinical benefit to apremilast in people with Psoriasis as compared to allele T.
Notes: "Allele-based association tests detected 64 SNPs displaying nominal p values < 0.05 (Table 2) including 10 SNPs with p values ≤ 0.01. " Table 2 shows frequency of minor allele is responders and non-responders. Responder status maybe defined by PASI score improvement greater than 75% after 24–36 weeks of treatment.
Article: Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis
Gene: HLA-DRB1
Variant/haplotype: HLA-DRB1*04:01, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:10, HLA-DRB1*10:01
Drug(s): abatacept
Phenotype category: Efficacy
Significant: yes
Association: HLA-DRB1 *04:01 + *04:04 + *04:05 + *04:10 + *10:01 is associated with increased clinical benefit to abatacept in people with Arthritis, Rheumatoid.
Notes: "Intriguingly, patients with Val11 of HLA-DRB1 SE exhibited a more favorable response to abatacept (OR = 6.46 [1.65–43.17], P = 5.4 × 10–3)" "SE with Val11 (*04:01, *04:04, *04:05, *04:08, *04:10, *10:01)"
Article: No significant influence of OCT1 genotypes on the pharmacokinetics of morphine in adult surgical patients
Gene: SLC22A1
Variant/haplotype: rs34130495
Drug(s): morphine
Phenotype category: Metabolism/PK
Significant: no
Association: Allele A is not associated with exposure to morphine in people with Pain, Postoperative as compared to allele G.
Notes: Analyzed as part of haplotypes with rs12208357, rs34059508 and rs72552763. There was a non-significant trend for patients carrying reduced function alleles to have increased exposure to morphine, but the change in exposure is not large enough to be of clinical importance.
Article: Pharmacogenetic Variants Associated with Fluoxetine Pharmacokinetics from a Bioequivalence Study in Healthy Subjects
Gene: CYP2D6
Variant/haplotype: rs1135840
Drug(s): fluoxetine
Phenotype category: Metabolism/PK
Significant: yes
Association: Allele C is associated with increased concentrations of fluoxetine in healthy individuals as compared to allele G.
Notes: "The CYP2D6*10 haplotype, related to decreased CYP2D6 function (poor drug metabolism), was found in only one volunteer (subject 25), based on CYP2D6 rs1065852 (haplotype A/A) and rs11358490 (haplotype C/C). As shown in Table 2, t1/2 was three times higher (106.9 h) for this subject than the overall mean (31.02 h). AUCs and t1/2 were statistically different between genotypes of CYP2D6 rs1065852 (p < 0.001). Stratification of subjects based on CYP2D6 genotypes confirmed the difference in the PK profiles, based on the three SNVs found in this study (rs1065852, rs1135840, and rs28371703)"
Article: Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy
Variant/haplotype: rs746460
Drug(s): anastrozole, exemestane
Phenotype category: Efficacy
Significant: no
Association: Allele T is not associated with increased response to anastrozole and exemestane in women with Breast Neoplasms as compared to allele C.
Notes: Patients included postmenopausal women with resected stage I–III breast cancer that was ERa and/or PgR positive and randomized to five years of anastrozole or exemestane. Did not reach statistical significance for GWAS (P<5 x 10^-8).
Article: A novel mutant variant of the CYP2D6 gene (CYP2D6 17) common in a black African population: association with diminished debrisoquine hydroxylase activity
Gene: CYP2D6
Variant/haplotype: CYP2D6*17
Drug(s): debrisoquine
Phenotype category: Metabolism/PK
Significant: not stated
Association: CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine.
Notes: A subject with an debrisoquine MR of 10.5 with is higher than for most EMs and close to the cut off for PM. Sequencing showed that the subject is homozygous for the *17 allele.
Article: Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226
Gene: CYP2C9
Variant/haplotype: CYP2C9 poor metabolizer
Drug(s): fulvestrant
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP2C9 intermediate metabolizer and poor metabolizer is associated with increased concentrations of fulvestrant in people with Breast Neoplasms and Neoplasm Metastasis as compared to CYP2C9 normal metabolizer and ultrarapid metabolizer.
Notes: Alleles measured included CYP2C9*2, CYP2C9*3 (or*18), CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*9, CYP2C9*10, CYP2C9*11, CYP2C9*12, CYP2C9*13, CYP2C9*15, CYP2C9*25 and CYP2C9*27. Alleles and phenotypes were modeled after CPIC. "participants with low CYP2C9 activity had lower anastrozole concentrations and higher fulvestrant concentrations than participants with high CYP2C9 activity"
Article: Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril
Gene: CES1
Variant/haplotype: rs71647871
Drug(s): quinapril
Phenotype category: Metabolism/PK
Significant: no
Association: Genotype CT is not associated with metabolism of quinapril in healthy individuals as compared to genotype CC.
Notes: This was a fixed-order crossover study with two phases: following overnight fasting participants took a 10 mg dose of quinapril and, after a washout period of at least 1 week, a 10 mg dose of enalapril with 150 ml water in the morning and EDTA-prepared blood samples were drawn before and up to 24 hr, and up to 48 h after ingestion for the determination of the concentrations of quinapril and its metabolite quinaprilat, as well as enalapril and its metabolite enalaprilat. Urine was collected up to 12 h after quinapril and enalapril. Only AUC (0-infinity) and amount excreted in urine of enalaprilat were significantly different between genotype groups. Other PK parameters that were tested and not significantly different were Cmax, Tmax, T(1/2), and renal clearance.
Article: Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response
Gene: CYP2C9
Variant/haplotype: CYP2C9*1, CYP2C9*2, CYP2C9*3
Drug(s): meloxicam
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP2C9 *3 + *2 are associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.
Notes: The population PK model predicted CL for meloxicam was decreased by 15%, 29%, 40%, 55%, and 80% in subjects with CYP2C9*1/*2, *2/*2, *1/*3, *2/*3, and *3/*3 genotypes, respectively, compared with that in subjects with the CYP2C9*1/*1 genotype. The effect of *2 on metabolism is moderate compared to *3.
Article: UGT1A6 and UGT2B15 Polymorphisms and Acetaminophen Conjugation in Response to a Randomized, Controlled Diet of Select Fruits and Vegetables
Gene: UGT1A6
Variant/haplotype: UGT1A6*1a, UGT1A6*2a
Drug(s): acetaminophen
Phenotype category: Metabolism/PK
Significant: yes
Association: UGT1A6 *2a/*2a + *1a/*2a is associated with increased metabolism of acetaminophen in healthy individuals as compared to UGT1A6 *1a.
Notes: Acetaminophen gluc/acetaminophen ratio was lower in *1/*1 subjects than *1/*2 and *2/*2 subjects. Please note UGT1A6*2 was determine using rs2070959 and rs1105879 and no subtype was classified in the study.
Article: Genome-Wide Association Study of Serum Creatinine Levels during Vancomycin Therapy
Gene: MIA3
Variant/haplotype: rs10495197
Drug(s): vancomycin
Phenotype category: Metabolism/PK
Significant: no
Association: Allele T is not associated with trough concentration of vancomycin as compared to allele C.
Notes: The SNP was not associated with trough levels of vancomycin (first vancomycin trough documented in EMR after at least 3 doses vancomycin). Elimination constants were also calculated.
Article: A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression
Gene: HTR7
Variant/haplotype: rs7905446
Drug(s): escitalopram
Phenotype category: Efficacy
Significant: yes
Association: Genotype TT is associated with decreased response to escitalopram in people with Depression as compared to genotypes GG + GT.
Notes: The GG and GT genotypes were associated with treatment remission.
Article: Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
Gene: SLCO1B1
Variant/haplotype: rs2900478
Drug(s): hmg coa reductase inhibitors
Phenotype category: Efficacy
Significant: yes
Association: Allele A is associated with decreased response to hmg coa reductase inhibitors as compared to allele T.
Notes: Carriers of this variant respond to statins with a 1.6% smaller LDL-C lowering effect per minor allele compared with non-carriers.
Article: The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
Gene: CYP3A4
Variant/haplotype: rs35599367
Drug(s): tacrolimus
Phenotype category: Metabolism/PK
Significant: no
Association: Allele A is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to allele G.
Notes: A single steady-state concentration of tacrolimus was collected for each patient 2-7 wks post-transplant and compared to dose of tacrolimus administered to patients at Oslo University Hospital. Reported concentrations are "steady-state dose-adjusted concentration" of tacrolimus. Steady-state is defined as at least 3 days after last dose adjustment for Tac and 4 days for cyclosporine.
Article: Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients
Gene: SLCO1B1
Variant/haplotype: rs2306283
Drug(s): tacrolimus
Phenotype category: Metabolism/PK
Significant: no
Association: Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.
Notes: This study was attempting to validate reported variants and tacrolimus trough concentration in a large population of African American and European American kidney transplant patients.
Article: CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA
Gene: LRP1
Variant/haplotype: rs11172113
Drug(s): botulinum toxin type a
Phenotype category: Efficacy
Significant: no
Association: Allele C is not associated with response to botulinum toxin type a in women with Migraine NOS as compared to allele T.
Notes: No significant difference in allele frequency between responders and non-responders.
Article: Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance
Gene: NR1I2
Variant/haplotype: rs2472677
Drug(s): donepezil
Phenotype category: Metabolism/PK
Significant: no
Association: Genotype TT is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype CC.
Notes: Genotypes of CC, CT and TT did not influence donepezil clearance in a covariate model.